Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100® Moderate Buffer UCITS ETF - March 14.07.2026 QMAR.LN IE0006S0EBF2 50,002.00 USD 1,243,142.78 24.862  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 14.07.2026 FTEI.LN IE000TIZ5AP4 250,002.00 EUR 5,369,591.12 21.478  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF- June 14.07.2026 MJUN LN IE000CO3P697 150,002.00 USD 3,809,104.09 25.394  ...
-

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 14.07.2026 FTAI IE000YIQZ0H6 225,002.00 USD 6,746,511.03 29.984  ...
-

Omdia:2026年第二季度全球智能手机市场下滑4%,苹果与三星逆势增长

伦敦--(BUSINESS WIRE)--(美国商业资讯)-- 根据Omdia最新研究,2026年第二季度全球智能手机出货量同比下降4%。持续的存储器供应危机扰乱了市场供应,并推高了关键元器件成本,进一步加剧了市场压力。当前市场正呈现明显的两极分化,不同厂商在应对策略上出现显著差异,主要受到战略重点、市场规模、价格段侧重以及目标用户群体等多重因素影响。 其中,三星和苹果逆势实现出货量增长,并分别较2025年第二季度提升2%和4%的市场份额,成为少数在整体市场下行背景下仍实现增长的厂商。 2026年第二季度,三星继续以22%市场份额稳居全球智能手机第一,主要得益于稳健的市场需求以及充足的产品供应。受Galaxy S26系列延期发布影响,部分高端市场需求顺延至第二季度释放。同时,随着中国智能手机厂商转向更为谨慎的市场策略,缩减产品线并提高产品出货价格,三星在入门级市场进一步扩大了市场份额。 苹果在2026年第二季度创下历年来最佳同期表现,在传统淡季实现20%的市场份额,创下第二季度份额历史新高。iPhone 17系列带动了苹果历史上表现最强劲的iPhone换机升级周期之一。与此同时,,苹果...
-

Samsung wird Lizenznehmer und Lizenzgeber für Sisvel's Wi-Fi-Multimode-Pool

LUXEMBURG--(BUSINESS WIRE)--Samsung Electronics hat sich als Lizenznehmer des Sisvel Wi-Fi Multimode-Pools registriert und wird im Rahmen des Programms zudem als Lizenzgeber tätig. Das südkoreanische Unternehmen ist ein weltweit führender Forschungs- und Entwicklungskonzern, gehört zu den weltweit führenden Smartphone-Herstellern und nimmt auch in vielen anderen Produktkategorien der Elektronikbranche eine führende Rolle ein. Deshalb bestätigt die Entscheidung von Samsung nicht nur die Stellung...
-

Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch

LONDON--(BUSINESS WIRE)--Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the...
-

Samsara Study Reveals Equipment Theft and Loss Costs Mid-Size Operations an Average of £9.7M Annually

LONDON--(BUSINESS WIRE)--New Samsara research finds untracked operations are 70% more likely to face significant losses...
-

Latent Labs Launches Latent-Y to Researchers Worldwide — With Free Daily Access and On-Demand Credits for Larger Campaigns

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Today, Latent Labs launches Latent-Y, its lab-validated drug design agent, to researchers worldwide through the Latent Labs Platform. Any approved researcher can now access Latent-Y for free, with a daily design quota included at no cost. For larger campaigns, researchers can purchase additional design credits on demand. Latent-Y is an AI agent for drug design. It takes a therapeutic goal, specified in written language or as a scientific publication, and...